全球分子即时诊断检测(使用 NAAT)市场,按产品(仪器和消耗品及试剂)、适应症(呼吸道感染检测、性传播感染 (STI)检测、胃肠道感染检测等)、最终用户(实验室、医院、诊所、门诊中心、家庭护理、辅助生活设施等)、检测模式(基于处方的检测和 OTC 检测)、分销渠道(医院药房、零售药房和网上药房)– 行业趋势和预测到 2028 年。
分子诊断即时检测(使用 NAAT)市场分析与洞察
全球分子即时检测(使用 NAAT)市场预计将增长,因为医疗设施和基础设施的改善以及医院、实验室和诊所采用即时检测,这些可以推动市场的增长。预计推动分子即时检测(使用 NAAT)市场发展的其他因素包括传染病的流行率上升。
其他因素,例如缺乏熟练的专业人员和定制分子即时检测(使用 NAAT)的高成本,阻碍了全球分子即时检测(使用 NAAT)市场的增长。另一方面,医疗支出的增加和拥有发达医院的新兴国家为全球分子即时检测(使用 NAAT)市场的增长提供了机会。
Data Bridge Market Research 分析,全球分子即时诊断(使用 NAAT)市场从 2021 年到 2028 年将以 10.8% 的复合年增长率增长。
报告指标 |
细节 |
预测期 |
2021 至 2028 年 |
基准年 |
2020 |
历史岁月 |
2019 |
定量单位 |
收入(百万美元),定价(美元) |
涵盖的领域 |
按产品(仪器和耗材及试剂)、适应症(呼吸道感染检测、性传播感染 (STI) 检测、胃肠道感染检测等)、最终用户(实验室、医院、诊所、门诊中心、家庭护理、辅助生活设施等)、检测方式(处方检测和非处方药检测)、分销渠道(医院药房、零售药房和网上药房) |
覆盖国家 |
北美(美国、加拿大)、欧洲(英国、德国、法国、西班牙、意大利、欧洲其他地区)、南亚(巴基斯坦、孟加拉国、印度、南亚其他地区)、东南亚(新加坡、马来西亚、越南、印度尼西亚、泰国、菲律宾、东南亚其他地区)、中东(沙特阿拉伯、阿联酋、埃及、以色列和中东其他地区)和非洲(南非、肯尼亚、尼日利亚和非洲其他地区) |
涵盖的市场参与者 |
SD Biosensor, Inc.、Abbott、F.Hoffmann-La Roche Ltd.、Danaher、Thermo Fisher Scientific Inc、binx Health, Inc.、Lucira、Meridian Bioscience、Quantumdx Group Ltd.、BD、Biomérieux Sa、Qiagen、Quidel Corporation、Sysmex Corporation、Bio-Rad Laboratories, Inc.、Sekisui Diagnostic、Randox Laboratories Ltd.、GenMark Diagnostics、Seegene Inc. Grifols SA、Wondfo、Oxford Nanopore Diagnostic、PerkinElmer Inc. 和 Co-Diagnostic, |
全球分子诊断即时检测(使用 NAAT)市场定义
POCT 的特点是可以在患者附近进行的检测,可以立即做出医疗决策,包括结果和监测。现在进入临床使用的 POCT 设备基于核酸扩增技术 (NAAT),本文将其定义为第二代设备。与第一代 POCT 相比,这些平台的灵敏度通常提高 60% 到 90%,并且需要便携式仪器,占地面积约为 30 厘米 x 30 厘米。这些仪器主要用于通过 NAAT 技术对各种疾病进行分子检测,例如HIV、HPV 和呼吸系统疾病。NAAT 是核酸扩增技术,可以通过检测病原体的 DNA 或 RNA 来识别病原体。
在全球大流行中,为了协同提高 NAAT 的灵敏度和 POCT 检测的易用性,设计了基于微型 NAAT 的 POCT 设备和检测,以更快地筛查和诊断 COVID-19,这也推动了市场的增长。
全球分子诊断即时检测(使用 NAAT)市场动态
本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容:
驱动程序
- 慢性病患病率上升
众所周知,健康衰退始于年龄的增长。随着慢性病的发病率随时间推移而增长,与发病率相关的因素也随之增加。肥胖/超重人口数量众多也增加了全球各个地区慢性病的患病率。HPV、STI 和 TB 等慢性病数量的增加,导致人们选择基于 NAAT 的即时检测和产品进行检测。因此,这将推动未来几年全球分子即时检测(使用 NAAT)市场的增长。
- 诊断率提高
随着癌症、贫血、二型糖尿病等慢性病的成功诊断率不断提高,医疗专业人员的素质不断提高,定期为专业人员提供检测培训,以提高该地区的诊断率。随着疾病负担的增加,诊断率也在提高。随着诊断技术的进步,接受诊断的人数也在增加。
- 家庭护理检测的偏好上升
家庭医疗保健偏好使临床信息可以在正确的时间和地点获得。它还将有助于减少错误并在确保质量的情况下提高安全性。它们还可以在发生医疗紧急情况时为老年人提供帮助。医疗保健领域已经进行了许多战略性变革,以解决即时检测的好处。根据世界卫生组织 (WHO) 的数据,65 岁及以上人口的数量预计将从 2010 年的 5.24 亿增加到 2050 年的约 15 亿,其中发达国家占增长的大部分。
机会
- 市场参与者采取的战略举措
全球慢性和非慢性疾病负担的增加,加上非洲和亚洲老年人口的增加,对开发新试剂盒和分子即时检测解决方案的需求越来越大,这些试剂盒和解决方案具有更好的功效和更少的耗时。为了在该地区提供诊断和筛查,市场参与者通过合作和协议,通过试剂盒和仪器为全球人口提供优质护理。
- 医疗支出上升
增加医疗支出和基础设施可以帮助患者轻松接受先进治疗,从而获得更好的诊断、手术和治疗,以快速康复。即时检测设备有利于检测各种疾病,并使用即时检测软件和解决方案支持治疗计划。医疗支出包括自付费用(人们支付医疗费用)、政府支出以及医疗保险和非政府组织活动等来源。
限制/挑战
- 产品成本高
即时检测产品的开发过程需要相当可观的成本。由于需要确定概念,必须采购材料,并且必须考虑交货时间。此外,这个过程非常耗时,因为设备设计需要足够的时间才能完全成熟,然后才能投入市场使用。
- 与实验室检测结果不一致
与实验室检测标准的结果相比,NAAT 检测结果有所不同。实验室检测更先进,遵循实验室检测的流程、协议和科学,并与准确分析、验证和记录效果所需的技术完全集成。然而,POCT/NAAT 无疑与缺乏精确的结果有关。分子 POCT 无法完成标准化,其他关键标准无法实现标准化和不同的基本标准。这对全球分子即时检测市场来说是一个重大挑战。PoC 测试有时可能会提供错误的结果,并且测试结果存在差异。
COVID-19 对全球分子诊断即时检测(使用 NAAT)市场的影响
COVID-19 对分子即时检测(使用 NAAT)市场产生了重大影响。由于在线销售的不断增长和产品的技术进步,COVID-19 在更高水平上对分子即时检测(使用 NAAT)产品的价格和需求产生了积极影响。COVID-19 大流行的爆发对市场的增长产生了积极影响,因为对分子即时检测(使用 NAAT)的需求很高,尤其是在各个医院。由于 COVID-19 病例的激增仍在持续,大多数医院目前优先考虑 COVID-19 治疗,这也增加了分子即时检测(使用 NAAT)的使用。此外,许多国际政府和医疗保健组织都支持这些产品的供应,因为它们在危急情况下具有高度优先性。
最新动态
- 2021 年 11 月,罗氏公司宣布,罗氏连续第十三年被评为道琼斯可持续发展指数中最具可持续性的三大医疗保健公司之一。这增加了预测期内的业务能力和业务扩张
- 2021 年 10 月,赛默飞世尔科技公司获得 FDA 批准,用于 TaqMan COVId-19 检测 SARS-COV 分子检测。这增加了公司的产品组合,并在预测期内为公司收入做出了贡献
全球分子诊断即时检测(使用 NAAT)市场范围
全球分子即时检测(使用 NAAT)市场根据产品、适应症、最终用户、检测方式和分销渠道分为五个显著的细分市场。这些细分市场之间的增长将有助于分析行业中的市场增长细分市场,并为用户提供有价值的市场概览和市场洞察,帮助他们做出战略决策,确定核心市场应用。
产品
- 仪器
- 耗材和试剂
根据产品,全球分子诊断即时检测(使用 NAAT)市场分为仪器和消耗品以及试剂。
指征
- 性传播感染 (STI) 检测
- 呼吸道感染检测
- 胃肠道感染检测
- 其他的
根据适应症,全球分子诊断即时检测(使用 NAAT)市场分为性传播感染 (STI) 检测、呼吸道感染检测、胃肠道感染检测等。
最终用户
- 实验室
- 医院
- 诊所
- 流动中心
- 家庭护理
- 辅助生活设施
- 其他的
根据最终用户,全球分子护理点检测(使用 NAAT)市场分为实验室、医院、诊所、门诊中心、家庭护理、辅助生活设施等。
测试方式
- 基于处方的测试
- OTC测试
根据测试模式,全球分子诊断即时检测(使用 NAAT)市场分为处方检测和 OTC 检测。
分销渠道
- 医院药房
- 零售药店
- 网上药店
根据分销渠道,全球分子诊断即时检测(使用 NAAT)市场分为医院药房、零售药房和在线药房。
全球分子诊断即时检测(使用 NAAT)市场区域分析/见解
全球分子诊断即时检测(使用 NAAT)市场根据产品、适应症、最终用户、检测模式和分销渠道分为五个显著部分。
全球分子即时诊断检测(使用 NAAT)市场分为北美(美国、加拿大)、欧洲(英国、德国、法国、西班牙、意大利、欧洲其他地区)、南亚(巴基斯坦、孟加拉国、印度、南亚其他地区)、东南亚(新加坡、马来西亚、越南印度尼西亚、泰国、菲律宾、东南亚其他地区)、中东(沙特阿拉伯、阿联酋、埃及、以色列和中东其他地区)和非洲(南非、肯尼亚、尼日利亚和非洲其他地区)。
北美在全球分子即时检测(使用 NAAT)市场占据主导地位,市场份额和市场收入的复合年增长率约为 12.1%。在预测期内,它将继续保持主导地位。这是由于传染病和慢性病的发病率不断上升,以及医院采用即时检测。
竞争格局和全球分子诊断即时检测(使用 NAAT)市场份额分析
全球分子即时检测(使用 NAAT)市场竞争格局提供了有关竞争对手的详细信息。 其中包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、公司优势和劣势、产品发布、监管指南、品牌分析、产品批准、产品有效载荷、应用主导地位、技术生命线曲线。 以上提供的数据点仅与公司对全球分子即时检测(使用 NAAT)市场的关注有关。
丹纳赫是市场主导者。全球分子即时检测(使用 NAAT)市场的其他主要参与者包括 SD Biosensor, Inc.、Abbott、F.Hoffmann-La Roche Ltd.、Thermo Fisher Scientific Inc、binx Health, Inc.、Lucira、Meridian Bioscience、Quantumdx Group Ltd.、BD、Biomérieux Sa、Qiagen、Quidel Corporation、Sysmex Corporation、Bio-Rad Laboratories, Inc.、Sekisui Diagnostic、Randox Laboratories Ltd.、GenMark Diagnostics、Seegene Inc. Grifols SA、Wondfo、Oxford Nanopore Diagnostic、PerkinElmer Inc. 和 Co-Diagnostic 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 DISTRIBUTION CHANNEL LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTERS FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 ANNUAL TEST VOLUME: FOR ALL COUNTRIES
4.3.1 CEPHEID
4.3.2 THERMO FISHER SCIENTIFIC INC.
4.3.3 HOLOGIC, INC.
4.3.4 BD
4.3.5 F. HOFFMANN-LA ROCHE LTD
4.4 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY
4.5 DISTRIBUTORS
4.5.1 NORTH AMERICA
4.5.2 EUROPE
4.5.3 SOUTH ASIA
4.5.4 SOUTH EAST ASIA
4.5.5 MIDDLE EAST
4.5.6 AFRICA
5 REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES
6.1.2 IMPROVING DIAGNOSIS SEEKING RATE
6.1.3 RISING TECHNOLOGICAL ADVANCEMENTS
6.1.4 RISING GERIATRIC POPULATION ACROSS GLOBE
6.1.5 RISING PREFERENCE FOR HOMECARE TESTING
6.2 RESTRAINTS
6.2.1 PRODUCT RECALLS
6.2.2 HIGH COSTS OF PRODUCTS
6.2.3 NON-AVAILABILITY OF RELEVANT AND APPROPRIATE KITS
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS
6.3.2 RISING HEALTHCARE EXPENDITURE
6.3.3 PANDEMIC OUTBREAK OF COVID-19
6.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS
6.4 CHALLENGES
6.4.1 LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES
6.4.2 LACK OF ACCESSIBILITY
7 IMPACT OF COVID-19 ON THE GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY CHAIN
7.4 KEY INITIATIVES BY MARKET PLAYERS DURING THE COVID 19
7.5 CONCLUSION:
8 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 CONSUMABLES & REAGENTS
8.3 INSTRUMENTS
8.3.1 MOBILE PLATFORM (SMALL & PORTABLE)
8.3.2 FACILITY-BASED PLATFORMS (LARGE POCT PLATFORM)
9 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION
9.1 OVERVIEW
9.2 RESPIRATORY INFECTIONS TESTING
9.2.1 COVID-19
9.2.2 FLU B
9.2.3 FLU A
9.2.4 RSV
9.2.5 TUBERCULOSIS
9.2.6 PNEUMONIA (PNEUMOCOCCAL PNEUMONIA)
9.2.7 OTHERS
9.3 SEXUALLY TRANSMITTED INFECTION (STI) TESTING
9.3.1 TV
9.3.2 CT
9.3.3 NG
9.3.4 HPV
9.3.5 HSV
9.3.6 MG
9.3.7 UU
9.3.8 MH
9.3.9 OTHERS
9.4 GASTROINTESTINAL TRACT INFECTIONS TESTING
9.4.1 GROUP B STREPTOCOCCUS
9.4.2 SHIGA TOXIN
9.4.3 H. PYLORI
9.5 OTHERS
10 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER
10.1 OVERVIEW
10.2 LABORATORIES
10.2.1 POLYMERASE CHAIN REACTION
10.2.2 ISOTHERMAL AMPLIFICATION
10.3 HOSPITAL
10.3.1 POLYMERASE CHAIN REACTION
10.3.2 ISOTHERMAL AMPLIFICATION
10.4 CLINICS
10.4.1 POLYMERASE CHAIN REACTION
10.4.2 ISOTHERMAL AMPLIFICATION
10.5 AMBULATORY CENTER
10.5.1 POLYMERASE CHAIN REACTION
10.5.2 ISOTHERMAL AMPLIFICATION
10.6 HOMECARE
10.6.1 POLYMERASE CHAIN REACTION
10.6.2 ISOTHERMAL AMPLIFICATION
10.7 ASSISTED LIVING FACILITIES
10.7.1 POLYMERASE CHAIN REACTION
10.7.2 ISOTHERMAL AMPLIFICATION
10.8 OTHERS
11 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING
11.1 OVERVIEW
11.2 PRESCRIPTION-BASED TESTING
11.3 OTC TESTING
12 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 HOSPITAL PHARMACY
12.3 RETAIL PHARMACY
12.4 ONLINE PHARMACY
13 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION
13.1 OVERVIEW
13.2 NORTH AMERICA
13.2.1 U.S.
13.2.2 CANADA
13.3 EUROPE
13.3.1 U.K.
13.3.2 GERMANY
13.3.3 ITALY
13.3.4 FRANCE
13.3.5 SPAIN
13.3.6 REST OF EUROPE
13.4 SOUTH ASIA
13.4.1 INDIA
13.4.2 PAKISTAN
13.4.3 BANGLADESH
13.4.4 REST OF SOUTH ASIA
13.5 SOUTH EAST ASIA
13.5.1 SINGAPORE
13.5.2 VIETNAM
13.5.3 THAILAND
13.5.4 MALAYSIA
13.5.5 INDONESIA
13.5.6 PHILIPPINES
13.5.7 REST OF SOUTH EAST ASIA
13.6 MIDDLE EAST
13.6.1 SAUDI ARABIA
13.6.2 U.A.E
13.6.3 ISRAEL
13.6.4 EGYPT
13.6.5 REST OF MIDDLE EAST
13.7 AFRICA
13.7.1 SOUTH AFRICA
13.7.2 KENYA
13.7.3 NIGERIA
13.7.4 REST OF AFRICA
14 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: GLOBAL
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
14.3 COMPANY SHARE ANALYSIS: EUROPE
14.4 COMPANY SHARE ANALYSIS: SOUTH ASIA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 DANAHER
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 THERMO FISHER SCIENTIFIC INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 BD
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 F.HOFFMANN-LA-ROCHE LTD.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.5 ABBOTT
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENTS
16.6 BINX HEALTH, INC.
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENT
16.7 BIOMERIEUX SA
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENT
16.8 CO-DIAGNOSTICS, INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENTS
16.9 GENMARK DIAGNOSTICS, INC
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENT
16.1 GRIFOLS, S.A.
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
16.11 LUCIRA HEALTH INC.
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENTS
16.12 MERIDIAN BIOSCIENCE
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENTS
16.13 QUANTUMDX GROUP LTD.
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENTS
16.14 QUIDEL CORPORATION
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENT
16.15 SD BIOSENSOR, INC.
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 SEKISUI DIAGNOSTICS (A SUBSIDIARY OF SEKISUI MEDICAL)
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENT
16.17 SYSMEX (A SUBSIDIARY OF SYSMEX CORPORATION
16.17.1 COMPANY SNAPSHOT
16.17.2 REVENUE ANALYSIS
16.17.3 PRODUCT PORTFOLIO
16.17.4 RECENT DEVELOPMENT
16.18 WONDFO
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
表格列表
TABLE 1 CEPHEID: ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 2 THERMO FISHER SCIENTIFIC INC. : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 3 HOLOGIC, INC. : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 4 BD : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 5 F. HOFFMANN-LA ROCHE LTD : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 6 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY, 2020 (UNITS)
TABLE 7 DISTRIBUTORS ACROSS NORTH AMERICA
TABLE 8 DISTRIBUTORS ACROSS EUROPE
TABLE 9 DISTRIBUTORS ACROSS SOUTH ASIA
TABLE 10 DISTRIBUTORS ACROSS SOUTH EAST ASIA
TABLE 11 DISTRIBUTORS ACROSS MIDDLE EAST
TABLE 12 DISTRIBUTORS ACROSS AFRICA
TABLE 13 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 14 GLOBAL CONSUMABLES & REAGENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 GLOBAL INSTRUMENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 GLOBAL INSTRUMENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 17 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 18 GLOBAL RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 GLOBAL RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 20 GLOBAL SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 GLOBAL SEXUALLY TRANSMITTED IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 22 GLOBAL GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 GLOBAL RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 24 GLOBAL OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 26 GLOBAL LABOROTORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 GLOBAL LABOROTORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 28 GLOBAL HOSPITAL IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 GLOBAL HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 30 GLOBAL CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 GLOBAL CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 32 GLOBAL AMBULATORY CENTER IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 GLOBAL AMBULATORY CENTER IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 34 GLOBAL HOME CARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 GLOBAL HOME CARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 36 GLOBAL ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 GLOBAL ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 38 GLOBAL ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 40 GLOBAL PRESCRIPTION-BASED TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION 2019-2028 (USD MILLION)
TABLE 41 GLOBAL OTC TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 43 GLOBAL HOSPITAL PHARMACY IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 GLOBAL RETAIL PHARMACY IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 GLOBAL ONLINE PHARMACY IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 48 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 49 NORTH AMERICA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 50 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 51 NORTH AMERICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 52 NORTH AMERICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 53 NORTH AMERICA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 54 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 55 NORTH AMERICA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 56 NORTH AMERICA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 57 NORTH AMERICA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 58 NORTH AMERICA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 59 NORTH AMERICA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 60 NORTH AMERICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 61 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 62 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 63 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 64 U.S. INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 65 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 66 U.S. RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 67 U.S. SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 68 U.S. GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 69 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 70 U.S. LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 71 U.S. HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 72 U.S. CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 73 U.S. AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 74 U.S. HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 75 U.S. ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 76 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 77 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 78 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 79 CANADA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 80 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 81 CANADA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 82 CANADA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 83 CANADA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 84 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 85 CANADA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 86 CANADA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 87 CANADA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 88 CANADA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 89 CANADA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 90 CANADA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 91 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 92 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 93 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 94 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 95 EUROPE INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 96 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 97 EUROPE RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 98 EUROPE SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 99 EUROPE GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 100 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 101 EUROPE LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 102 EUROPE HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 103 EUROPE CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 104 EUROPE AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 105 EUROPE HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 106 EUROPE ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 107 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 108 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 109 U.K. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 110 U.K. INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 111 U.K. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 112 U.K. RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 113 U.K. SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 114 U.K. GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 115 U.K. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 116 U.K. LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 117 U.K. HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 118 U.K. CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 119 U.K. AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 120 U.K. HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 121 U.K. ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 122 U.K. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 123 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 124 GERMANY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 125 GERMANY INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 126 GERMANY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 127 GERMANY RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 128 GERMANY SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 129 GERMANY GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 130 GERMANY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 131 GERMANY LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 132 GERMANY HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 133 GERMANY CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 134 GERMANY AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 135 GERMANY HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 136 GERMANY ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 137 GERMANY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 138 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 139 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 140 ITALY INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 141 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 142 ITALY RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 143 ITALY SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 144 ITALY GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 145 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 146 ITALY LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 147 ITALY HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 148 ITALY CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 149 ITALY AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 150 ITALY HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 151 ITALY ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 152 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 153 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 154 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 155 FRANCE INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 156 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 157 FRANCE RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 158 FRANCE SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 159 FRANCE GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 160 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 161 FRANCE LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 162 FRANCE HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 163 FRANCE CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 164 FRANCE AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 165 FRANCE HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 166 FRANCE ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 167 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 168 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 169 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 170 SPAIN INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 171 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 172 SPAIN RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 173 SPAIN SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 174 SPAIN GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 175 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 176 SPAIN LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 177 SPAIN HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 178 SPAIN CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 179 SPAIN AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 180 SPAIN HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 181 SPAIN ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 182 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 183 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 184 REST OF EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 185 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 186 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 187 SOUTH ASIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 188 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 189 SOUTH ASIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 190 SOUTH ASIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 191 SOUTH ASIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 192 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 193 SOUTH ASIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 194 SOUTH ASIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 195 SOUTH ASIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 196 SOUTH ASIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 197 SOUTH ASIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 198 SOUTH ASIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 199 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 200 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 201 INDIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 202 INDIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 203 INDIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 204 INDIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 205 INDIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 206 INDIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 207 INDIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 208 INDIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 209 INDIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 210 INDIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 211 INDIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 212 INDIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 213 INDIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 214 INDIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 215 INDIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 216 PAKISTAN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 217 PAKISTAN INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 218 PAKISTAN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 219 PAKISTAN RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 220 PAKISTAN SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 221 PAKISTAN GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 222 PAKISTAN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 223 PAKISTAN LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 224 PAKISTAN HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 225 PAKISTAN CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 226 PAKISTAN AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 227 PAKISTAN HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 228 PAKISTAN ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 229 PAKISTAN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 230 PAKISTAN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 231 BANGLADESH MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 232 BANGLADESH INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 233 BANGLADESH MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 234 BANGLADESH RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 235 BANGLADESH SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 236 BANGLADESH GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 237 BANGLADESH MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 238 BANGLADESH LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 239 BANGLADESH HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 240 BANGLADESH CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 241 BANGLADESH AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 242 BANGLADESH HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 243 BANGLADESH ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 244 BANGLADESH MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 245 BANGLADESH MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 246 REST OF SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 247 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 248 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 249 SOUTH EAST ASIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 250 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 251 SOUTH EAST ASIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 252 SOUTH EAST ASIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 253 SOUTH EAST ASIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 254 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 255 SOUTH EAST ASIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 256 SOUTH EAST ASIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 257 SOUTH EAST ASIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 258 SOUTH EAST ASIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 259 SOUTH EAST ASIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 260 SOUTH EAST ASIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 261 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 262 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 263 SINGAPORE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 264 SINGAPORE INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 265 SINGAPORE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 266 SINGAPORE RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 267 SINGAPORE SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 268 SINGAPORE GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 269 SINGAPORE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 270 SINGAPORE LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 271 SINGAPORE HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 272 SINGAPORE CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 273 SINGAPORE AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 274 SINGAPORE HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 275 SINGAPORE ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 276 SINGAPORE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 277 SINGAPORE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 278 VIETNAM MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 279 VIETNAM INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 280 VIETNAM MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 281 VIETNAM RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 282 VIETNAM SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 283 VIETNAM GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 284 VIETNAM MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 285 VIETNAM LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 286 VIETNAM HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 287 VIETNAM CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 288 VIETNAM AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 289 VIETNAM HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 290 VIETNAM ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 291 VIETNAM MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 292 VIETNAM MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 293 THAILAND MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 294 THAILAND INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 295 THAILAND MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 296 THAILAND RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 297 THAILAND SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 298 THAILAND GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 299 THAILAND MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 300 THAILAND LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 301 THAILAND HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 302 THAILAND CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 303 THAILAND AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 304 THAILAND HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 305 THAILAND ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 306 THAILAND MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 307 THAILAND MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 308 MALAYSIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 309 MALAYSIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 310 MALAYSIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 311 MALAYSIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 312 MALAYSIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 313 MALAYSIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 314 MALAYSIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 315 MALAYSIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 316 MALAYSIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 317 MALAYSIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 318 MALAYSIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 319 MALAYSIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 320 MALAYSIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 321 MALAYSIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 322 MALAYSIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 323 INDONESIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 324 INDONESIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 325 INDONESIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 326 INDONESIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 327 INDONESIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 328 INDONESIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 329 INDONESIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 330 INDONESIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 331 INDONESIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 332 INDONESIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 333 INDONESIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 334 INDONESIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 335 INDONESIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 336 INDONESIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 337 INDONESIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 338 PHILIPPINES MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 339 PHILIPPINES INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 340 PHILIPPINES MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 341 PHILIPPINES RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 342 PHILIPPINES SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 343 PHILIPPINES GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 344 PHILIPPINES MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 345 PHILIPPINES LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 346 PHILIPPINES HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 347 PHILIPPINES CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 348 PHILIPPINES AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 349 PHILIPPINES HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 350 PHILIPPINES ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 351 PHILIPPINES MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 352 PHILIPPINES MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 353 REST OF SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 354 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 355 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 356 MIDDLE EAST INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 357 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 358 MIDDLE EAST RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 359 MIDDLE EAST SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 360 MIDDLE EAST GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 361 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 362 MIDDLE EAST LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 363 MIDDLE EAST HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 364 MIDDLE EAST CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 365 MIDDLE EAST AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 366 MIDDLE EAST HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 367 MIDDLE EAST ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 368 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 369 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 370 SAUDI ARABIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 371 SAUDI ARABIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 372 SAUDI ARABIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 373 SAUDI ARABIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 374 SAUDI ARABIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 375 SAUDI ARABIAGASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 376 SAUDI ARABIAMOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 377 SAUDI ARABIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 378 SAUDI ARABIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 379 SAUDI ARABIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 380 SAUDI ARABIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 381 SAUDI ARABIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 382 SAUDI ARABIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 383 SAUDI ARABIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 384 SAUDI ARABIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 385 U.A.E MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 386 U.A.E INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 387 U.A.E MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 388 U.A.E RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 389 U.A.E SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 390 U.A.E GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 391 U.A.E MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 392 U.A.E LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 393 U.A.E HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 394 U.A.E CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 395 U.A.E AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 396 U.A.E HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 397 U.A.E ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 398 U.A.E MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 399 U.A.E MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 400 ISRAEL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 401 ISRAEL INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 402 ISRAEL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 403 ISRAEL RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 404 ISRAEL SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 405 ISRAEL GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 406 ISRAEL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 407 ISRAEL LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 408 ISRAEL HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 409 ISRAEL CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 410 ISRAEL AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 411 ISRAEL HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 412 ISRAEL ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 413 ISRAEL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 414 ISRAEL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 415 EGYPT MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 416 EGYPT INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 417 EGYPT MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 418 EGYPT RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 419 EGYPT SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 420 EGYPT GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 421 EGYPT MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 422 EGYPT LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 423 EGYPT HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 424 EGYPT CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 425 EGYPT AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 426 EGYPT HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 427 EGYPT ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 428 EGYPT MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 429 EGYPT MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 430 REST OF MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 431 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 432 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 433 AFRICA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 434 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 435 AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 436 AFRICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 437 AFRICA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 438 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 439 AFRICA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 440 AFRICA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 441 AFRICA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 442 AFRICA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 443 AFRICA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 444 AFRICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 445 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 446 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 447 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 448 SOUTH AFRICA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 449 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 450 SOUTH AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 451 SOUTH AFRICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 452 SOUTH AFRICA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 453 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 454 SOUTH AFRICA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 455 SOUTH AFRICA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 456 SOUTH AFRICA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 457 SOUTH AFRICA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 458 SOUTH AFRICA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 459 SOUTH AFRICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 460 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 461 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 462 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 463 KENYA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 464 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 465 KENYA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 466 KENYA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 467 KENYA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 468 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 469 KENYA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 470 KENYA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 471 KENYA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 472 KENYA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 473 KENYA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 474 KENYA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 475 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 476 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 477 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 478 NIGERIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 479 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 480 NIGERIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 481 NIGERIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 482 NIGERIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 483 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 484 NIGERIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 485 NIGERIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 486 NIGERIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 487 NIGERIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 488 NIGERIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 489 NIGERIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 490 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 491 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 492 REST OF AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
图片列表
FIGURE 1 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SEGMENTATION
FIGURE 2 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: MULTIVARIATE MODELLING
FIGURE 8 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: END USER OVERAGE GRID
FIGURE 11 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD
FIGURE 13 INCREASING PREVALENCE OF CHRONIC DISEASE AND IMPROVING DIAGNOSIS-SEEKING RATE ARE EXPECTED TO DRIVE THE GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET IN THE FORECAST PERIOD
FIGURE 14 CONSUMABLES AND REAGENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET IN 2021 & 2028
FIGURE 15 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR THE MOLECULAR POINT OF CARE TESTING (USING NAAT) MANUFACTURERS IN THE FORECAST PERIOD
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET
FIGURE 17 MEDICAL DEVICE SPENDING VS NATIONAL HEALTH EXPENDITURES, 2016
FIGURE 18 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, 2020
FIGURE 19 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, 2021-2028 (USD MILLION)
FIGURE 20 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, CAGR (2021-2028)
FIGURE 21 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 22 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, 2020
FIGURE 23 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, 2021-2028 (USD MILLION)
FIGURE 24 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, CAGR (2021-2028)
FIGURE 25 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 26 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, 2020
FIGURE 27 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, 2021-2028 (USD MILLION)
FIGURE 28 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, CAGR (2021-2028)
FIGURE 29 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, 2020
FIGURE 31 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, 2021-2028 (USD MILLION)
FIGURE 32 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, CAGR (2021-2028)
FIGURE 33 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, LIFELINE CURVE
FIGURE 34 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 35 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 36 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 37 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)
FIGURE 39 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY REGION (2020)
FIGURE 40 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY REGION (2021 & 2028)
FIGURE 41 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY REGION (2020 & 2028)
FIGURE 42 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)
FIGURE 43 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)
FIGURE 44 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)
FIGURE 45 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 46 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 47 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)
FIGURE 48 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)
FIGURE 49 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)
FIGURE 50 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 51 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 52 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)
FIGURE 53 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)
FIGURE 54 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)
FIGURE 55 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 56 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 57 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)
FIGURE 58 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)
FIGURE 59 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)
FIGURE 60 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 61 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 62 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)
FIGURE 63 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)
FIGURE 64 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)
FIGURE 65 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 66 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 67 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)
FIGURE 68 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)
FIGURE 69 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)
FIGURE 70 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 71 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 72 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)
FIGURE 73 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY SHARE 2020 (%)
FIGURE 74 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY SHARE 2020 (%)
FIGURE 75 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY SHARE 2020 (%)
FIGURE 76 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY SHARE 2020 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.